N1

,
()
2013 24
() , N 01-150 /

2013 30 N1

()


1. ..............................................................................................................................................

? ....................................................................................

.........................................................................................................

? ..............................................................................................................

......................................................................................................................................

2. .............................................................................................................................................

, , , ............................................................

...............................................................................

.........................................................................

.......................................................................................................................

.........................................................................................

...............................................................................................................................

...........................................................................................................................................

..................................................................................................

3. ....................................................................

...............................................................................................................................................................

.........................................................................................

4. .................................................................................................................

...................................................................................................................................

...........................................................................................................................

.............................................................................................................................
5. .......................................................................................

.................................................................

...............................................................................................................................................
......................................................................................................................
(-) ....................................................
(-) ..........................................................................................
....................................................................................

()................................................................................................................

.......................................................................................................................................................

.......................................................................................................

- :................................................................................................................................................

6.
.......................................................................................................................................

7. ..............................................

7.1. ,
................................................................................................................................................................

7.2. ....................................................................

7.3. ..............................................................................

7.4. , ..............................................

7.5. ........................................................

8. ...............................................................................................................

8.1. : , ( 2) ......................

8.2. -2 :
( 3)...................................................................................................................................................

8.3. 3 :
( 4) ......................
8.4.
....................................................................................

8.5 ........................................................................

8.6. 4 : ( 5)............................................

9. ............................................................

................................................................................................................................................................

9.1. : ......................................................................................................................

9.2 ...................................................................................................................

9.3 ...................................................................................................................

10. .....................................................................

11. ............................................

( 9) ......................................................................................................

...

12. ..............................................................

13. .....................................................................................................

14. ...............................................

15. ........

16. .......................................................................................................................................
( 1) ...............................................................................
( 2)....................................................................................................
- ( 3) ...............................................................................................
( 4) ........................................................................................................
- ( 5) ...............................................................................................
( 6) .............................................................................

( 7) ...............................................................................................
( 8) ..................................
( 9) ......................................................................................
( 10) ....................................................

17. .............................................................................................................................................
1 ........................................................................................................................
I ( 2).............................................................................................................................................
II ( 3)............................................................................................................................................
III ( 4)...........................................................................................................................................
IV ( 5) .........................................................................................................................................

18. ......................................................................................................................................
( 1) .................................................................................................................
( 2) .............................................................................

19. : ................................................................................................

20. : .................................................................................................


1.

,

(Mann, 1996).
, ,

.

()

, ,
:


;
,

;

;

;
,
;
.

.
.
,

, (
/ ).
, ,
, .
,

.
, ,

.
.
,
,
.
 ?

, ,
.
:
();
.

,
. , ,

.
.

. ICD10
: (F32),
(F33), (F34.1)
(38). ,

. , F41.2
F06.32 .
, ICD10
 , .
, , , 2
, (F34.1).
, ,

.
DSMIV-TR
(296.2), (296.3), (300.4)
,
(APA, 2000c).

(
).
,
, ,
.
 2.

, , ,

(: ) - -,
(. . )
- .

,

.

:
- /

, .
4 :
( ,
);
/ ;
;
( );
,
;
.
 , -
.
-
-.
, ,
., . ,
-
. ,
. ,
.
,
. - ,
, , ,
, . -
.

( ) ,
:
;
;
.
, , ,
.
,
. .
.
, ,
 .
,
.
. , ,
, .
- ,

. ,
, ,
(
2).
- :
;
;

,, ;
- (,
, . .)
;
.
: ,
, ,
, ,
, .

,
( , ).
 () :
;
;
;
;
;
;
;
;
.
,
,.
. ,

, .
.

. / ;
, ,
.
.

( ).


(, ),
.
 , .
.
. , ,
(
).
.
. ,

. .
,
.

, , (,
,
, ).
. ;
,
. ,
,
. ,
.
.
, .
, , , ,

.

,
( , ) .
: , ,
, , ,
( ).
,
.
.
,
.
, ,
2-3 . , ,
, .
,
.
-
. ,
.
,
.
-
. .
.
, : ,
.

.

(,,);
, ;
;
;
;
;
(, ) ;
, ;
-
- Anaesthezia psychica dolorosa;
;
;
;
, , , ,
;
- ;
,
,
.

- . :
, ,
, :
. ;
 , ,
, ,
.
,
. ,
, .

,
. ,
.

.
.
.
.

, .
. : ,
, , ,
. ,
:
, , ,
,
. ,
. ,
 . ,
( ).
. ,
.
,
, .

, -
, .

(Cotards syndrome),
1882 .
. , ,
,
. ,
. ,
. ,
,
.

,
. ,
, ,
 .
- .

,
.
, , ,
.
.
.


,
. ,
,
.


.
:
; -
;
;
;
.
,
( ).
,
 , .
. ,


(Quitkin et al, 1993; Joyce et al, 2004).

,
,
. ,
,
.
, : , (),
, , .
DSM-IV ( IV) ICD-10
( )
,
,
( ( 1).
,
,
, , .
, ,
,
,
. (,
) . , -
-
.
. .

. ;
, ,
, . ,
,
, ,
. ,
. , ,

(Judd et al, 1998, 2002 ); ,
-
.

.
, ( Lewis, 1956) ,

. ,
,
,

.
 ICD-10 -
, ,
,
,
,

ICD-10- ,
, , ,
. ICD-10-
, , ,
- ;
- ..
DCM-IV- .
,
,
. ,
,
. ,
,
. ,
,
.

,
,
 . ,
, , 2 , .
:

5 ;

;
, , , 2
, .

,
,
, ,
.
DCM-IV-
.

DSM-IV
( IV) ICD-10
( , ) .
 ICD-10
( , )
, :

, , ;

,
(F30);
:
(F10-F19)
(F00-F09).
A
- ;
;
.
B
;
;
;
;
;
;
.
:
A B .
( ) :
A B .
:
A B .

.
 - DSM-IV
( IV)

( )
. - : )
- )
.
1. - ,
, (,
) (.,
) .
2.
,
, ( ,
, ).
3.
(., 5%- );
.
4. .
5. - .
( ,
).
6. .
7. ,
( )
(
).
8.
(
).
9. (
),
, .
 (DSM-IV- )
:
5 ;
: 5
, ;
:
, ;
: ,
.
.

:
, /
.

3.

, , , DSM-IV-
, (Alonso et al, 2004):
12- 2-5% -;

(4-30 %). ,
, 10-20%- ;
2530 ;
 ,
;
1945
;
;
, ,
.
, ,
. , ,
,
. ,
. ,
, ,
, ,
. ,
.
(,
)
, . ,

. ,
, . ,
.
,
, ,
18-44 . 1945


.
, , ,
,
,
( Paykel, 2000).

4 (Alonso et
al, 2004). .

.
12- 2.6%,
2,3% (Pezawas et al, 2003).
,
.
.
:

16%- (12.3% 19.5% ).
ICD-10-
(Jenkins et al, 1997). (DSM-IV-
) 55 ,
9.8%- (Beekman, et al 1999).
 4.

,

10-15%-, 1-2%-
.
68%-,
- 23%- (Price 1977);
74% 43%- ( Angst 1966; Bertelsen et al. 1977).

,
,
(Garver, Devis 1979).
, (, , )
.

(Grahame-Smith D. G. 1992).
- -
( ) ,
,
MAO- .

,
. ,

 . -

,
(, , ). -
- ,
,
(
). ,
, -

.
Carroll B. (1982) ,
40-60%-,
- 80%-.
,
, ,
(. ,
, , , ) ,
.
, ,
,
.
.


(
), IV .


. -
.
, ,
. :
( )

(Mazure & Maciejewski, 2003).
. - ,

, .
. - Beck- 1967 ,
,, ,
,
. : )
- ,, ,
; )
- ,, ; )
- .

, -
,
6,
7 (Paykel et al. 1969, 1978; Brown, Harris 1978);
 -
, ,
, .
, ,
, ,
,, , ,
,
(Cassano & Fava., 2002).
,
(Drevets et al, 2008).

(Beck., 2008) .

5.

,
( 1).

.
()
(Wagner, 1997; Katon et al, 2001)
:

;


;


;


.


,
(, ,
)
.

,
.
(
) ,
//.
,
,

:
,
;
,
;
 ,
.
1620
.

,
,
- .. (Kuehner, 2005; Lewinsohn et al, 1989).
,
. 12
. 8 2
4 . .
, 610 , - .

.

() (Segal et al, 2002) 8
.
815 .

3 ( ( 2):
,
/
( , - (SSRI) ,
 (-,
SSNRI) (-
, SNRI ));
(-) ,
(
) () ;
5HT2 (,
, ) ,
5HT2 .
.
,
. ,
, .

.

,
. , ,
. ,
-
. ,
5HT2 ,
.
,

(Buckley et al, 1988).

-
2-4 .

.
. ,

( ).
,
:
, , .
300
/- (Burke, Preskorn, 1999). ,
,
.

:
;
;
(>200 )
;

(, );


: , ,
, ,
, . ,
,
.
;
, ,
; ;
- .
PR QT , ST
T- .
,
;
- (),
, , (
), ,
- ;
- , ,
, ;
.
-
. , ,
, - . .

,
.
 - ,
.

.
,
. .
,
, , , .
,
, , .
.

. ,

. ,
.
.

.

.

, -
2,2 (Cohen, 2000).


,
. , -
, , ,
.

, - ,
.

.

-2
,
-
(ACE) .


.
- ,
, .

, , , -
-.
.

, ,
, -
.
.

,
, -
, ,
.
.

,
.
, ,
. 25-50 /
50-75 / - .
1-2 ,
. 75 /-
, .
,

, .
(300
/-). .
225 /
.

, , 450 /-
.
300 / (Burke, Preskorn, 1999).
- ,
QT- , .
,
1 .

,
6 , .
,

.

(-)

-
.

.

, -
4-8 ,
. , , ,
20-30 , 48-
72 . - .

-
,
- .

. , -

(Anderson, 1999).

-
- ( ()
.
- , ,
. ,
. -
.
:
-:
20%-,
; , ; -
.
 :
, , , , ,
. -
, . ,
,
-, .
,
.

:
, .
. -
,
.

. -
, .
,
. -
- ,

.
:
-
. - -


(Khan, 2003). -

,
.
,
,
-
(Jick, 2004). , 4-
9 ,
(>90 ) .
9 40-
(Jick, 2004).
. ,

. , ,

- . ,
,
.

- -
,
. ( )
: , , .
( ( ).
 , ,
- . ,
,
, .
-
, .
-
, -
.

- - P-450-

.

-
-
. -

(Anderson, 1999). ,
, , .
-
;
;
;
;
;
 - .
-
, . -

.
, ,
-
, , .
- ,
,
.
,
,
. (50-150 ) ,
, ,
(Mir, Taylor, 1999).
,
-,
. , -
, -
. - ,
, .. , ,
( 6).

(-)
- ,

.
 , -
,
,
. - , ,
.

- ,
, , ,
.
.

-
-
. -
. -

(Thase, 1995).
( ( )
, ,
, , , ,
, , ,
.

, ,
- . ,
 ,

, , .

.
.
-
10%-. , -
4/5 , ,
.
-1- ,
.
.
.
.

,
, - ( )
.
.
,
.
- -
.
,
.
, ,
, .
- ,
, .

,
, , ,
- .

-

,
.
.
, -
.

-
, -,
.
6 - .
. -
.
.
 , , , 2

.

,
, , -
-, .

,
.
, , ,
. ,
.

, .
,
. -1-
.
. ,
,
. ,
, .
.
(6000 1),
 , ,
.
.

.
,
,
.

,

.
,
,

. ,

().

, ,
.
, ,
(Anderson, 1999). , -
, , -
(Smith, 2002).
 - .
, , , ,
. .
,
. , >150 /,
.
- .
,
, - .
,
-.
:
,

;
,
;
.
- ,
, , .
, 6 ,
1 .
.
, -
,
.
, ,
 - ,
. -
14 ,
7 - - .

M 1 /M 2 5HT 2C .
, 5HT 2C

, , ,
.
(,
) (Kennedy et
al, 2006; Montgomery et al, 2006). ,
(Montgomery et al, 2007) (Goodwin et
al, 2007). ,
(Stein et al , 2008).
, (Dolder et
al, 2008). ,
, , (Kennedy et al, 2008).
(Montgomery et al, 2004).

(Guilleminault et al, 2006). ,
. 2009 .
,
6 12 24
(European Medicines Agency, 2009).
 ()

.
,
:

;
.

, :
;
;
.

, .

: -
.
, -
, .
.
, - ,
.

- ,
- .
:
(
5- ) ,
;
- ,
, .
, - .

-
. -

30 - .
, -
. , .
,
,
.
, ,
.
- ,
. ,
.
. , ,
, .
 ,
. , ,
, .
-
.
-
. , ,
(Cohen, 2000).

-
- 3-4
100 000 . ,
.

.
.
: - ,
,
,
.
,
, .

.
-
. - . -
, -.


. , ,
. -

.

.
.
,
. ,
.

.
,
.
.
, ,
, ,
.
, ,
.
,
,
.
.

.
:
(
).
, ,
, .
.
,
.
50%- .

. -
,
.
-
,
. - 6- 12
. .
- ,
. ,
. , 6-8 ,
, -
. .

.

,
.

, .

-
,
. ,
.
,
.

(Rosenthal) 1984 . ,
,

(Eagles, 2004).

, ,
, .
 ,
2500-10000
.

, .
,
,
, :
;
;
.
,
, ,
.

,

45%-. : ,
, ,
. ,
.
.


. ,
, .
.
30 10000 2 2500 .
30-40 -.
45 1-2-
.
.

.

,
. .

() ,
, ,
. -
.
- 2 (),

. - ,
, .. -.
, 1/ (1 ), -.

.

- :

.
-- ,
(Martin, 2002).
,
, ,
.
.
.
 6.

:

,
, .
/
.


.
,
.


.
.


(
).
:
- -
?

?


,
,
, :
;

( 2 );

.
* (* )
:

;

, (,
, ,
)
.
:
( );
;
.


.

, ,
, , , 6 ,
. ,
.
, .

7.

7.1. ,

7.1.1. ,
:
,

( A, I, Khan and colleagues (2007);

.
. , ;
,
;
, ,
.
7.1.2.
:


-
;
,
.
7.1.3. ,
.

( C, III, Roberts et al, 2008).
7.1.4.
, .
:
;
;
( ).

7.2.

7.2.1.
,
, ,
. .
, ,
. .

7.3.
7.3.1.
:

. ,
;
()
,


( D, IV, Yager J, 1992).

7.4. ,

7.4.1. .
.

( A,
I, Mitchell et al., 2009).
7.4.2.
,
:

;
- (,
, );



.
7.4.3. ,

(
C, III, Bhugra, D. & Cochrane, R.2001).
:
;
;

;
-
.
7.4.4.

.

( C, III, Bhugra, D, Prasher, V. (1999).
7.4.5.
:
,
;
,
.
7.4.6.
.
 ( A, I, Harris, E. C. &
Barraclough, B. 1997);
,
;
;
, , .

7.5.

7.5.1.
.
(),
.
( A, I Badamgarav et al., 2003; II,
Gilbody et al., 2006):
;
.


7.5.2. ,
.

8.

,
( 1).

 .
,
( B, II Bower & Gilbody, 2005a) .

8.1. : , (
2)

8.1.1.
8.1.1.1. ,
,

.
8.1.1.2. ,

( A, II, Whooley, M. A., et al. 1997):

-
?

?
8.1.1.3. ,

,
.
8.1.1.4. ,

,
.
8.1.1.5. ,

,

 (
).
8.1.1.6. ,

, .
(
,
. ,

0- 10 . 4 ,
( C,
III, Roth AJ, et al. 1998).

8.1.2.

8.1.2.1. ,

(

).
8.1.2.2. ,
, , .
( B, II, MacMillan et
al, 2005; Palmer, 2003).
, ,
.
,
.
8.1.2.3.
, -
, ,
, .
, ,
.
, , , ,
/
.
8.1.2.4. :

;
;

.

8.2. -2 :
( 3)

8.2.1.

8.2.1.1. ,

.
,
(
) ( B, II, Barkow, 2004).

8.2.1.2. ( C,

III, NICE, 2004a)

;
,
;
;
.

8.2.1.3. , : (1)

; (2) ,
; (3)
, :
() ,
;
;
, , ;
, .

8.2.2.

8.2.2.1. ,
,
:
- ( A, II, Ayen,
2004);
( D, IV, Brown, 2005);
8.2.2.2. -

.
8.2.2.3. -

:
, ;
;
8-10 10 -12 ;
, 12-16 , .
8.2.2.4.

:
;
45 1 1014 (
12) ( A, II, Kazantzis, 2000).

8.2.3.

8.2.3.1.
,

,
, ( A, II, Kirsch, 2008;
Paykel, 1988):
();

( 2 );

.

8.3. 3 :

( 4)

8.3.1.

8.3.1.1.

,
, :
(
)
.
8.3.1.2.

()
( A, I Keller et al, 2000).
8.3.1.3. :

;

;

();

.
8.3.2.

:
8.3.2.1. :

,
;

;
,

, ,

( A, I , Gartlehner et al., 2008; Geddes
et al 2000);
, :
- ,
,

.

;
,

;

.
8.3.2.2. , ,

( )
. ,
, (
) .
8.3.2.3.
:
,

( ).
8.3.2.4.
.
:


;

;

;
.
8.3.2.5.
.
8.3.2.6.
( A, I Nicholson et al,
2006; A, II Roose et al, 2003).
 8.3.3.

8.3.3.1. ,

.
:

;

.
:
;
;
,
,
(, )
;
, ;
() .
8.3.3.2. , ,

2 . 2- 4-
, ,
, .
8.3.3.3. 30 ( ,

) , ,
1 ,
.
8.3.3.4.

,
:
,
,

,

, / (
,
); ,
.
8.3.3.5.
,
.
8.3.3.6. .

8.3.3.7.
2-4 , ,

.
8.3.3.8. 3-4 ,

(, )
:
,
,
.
8.3.3.9. 4 ,
2-4 .
8.3.3.10. , ( 2.4.2 ) :

;
;
.

8.3.4.

8.3.4.1.

.

, ():
, ;
, ,
(,

,
).
8.3.4.2. -

16-20 3-4 .
:
2 2-3 ,
;
3-4 3- 6
;
 15-20 5-6
.

8.3.5.

.

.
8.3.5.1. (,

)
,
.
8.3.5.2. ,

, ,
.
8.3.5.3. :

;
.
8.3.5.4.

:
,
 .

8.3.6.

8.3.6.1.
.
,
8.3.6.2.

:
,
;


.

8.4.

8.4.1.
8.4.1.1. ,

:
, ,
.
8.4.1.2. , .

,

;
, ,
,
;

,
;
.

8.4.2.
8.4.2.1. ,
,
.
:
;
,
, ,
.
8.4.2.2.

, , .

.
:
,
(
);
 ,
- .
:
- ,
;

,
( :
, , , ,
).
8.4.2.3.
(
).

8.4.3.
, (
) , ,
.
8.4.3.1. ( ):

,
;
;
;

;
;

, .
.
8.4.3.2.

,
:
,
- *, *, *
,
.
8.4.3.3. :

, 6 (
);
,
;
1

( A, I, Nierenberg et al, 2006; Cipriani et al, 2005).
8.4.3.4. ,

(
-
).
8.4.3.5. :

, ;
 *, *
,
;
,
.
8.4.4.
8.4.4.1.
,
().
8.4.4.2.

, ,

.

8.5 .

8.5.1.
,
6 .
, :

;
.
8.5.2. 6
:
;
;
 .
8.5.3.
,
() .
:
, ,
,
;
.
8.5.4.
2 .

(
, , )
( A, II, Baldwin et al, 2009; Gilbody et al, 2006):

, ;
-, ,
,
,
;
(,
,
).
8.5.5. 2
,
.
 8.5.6.
,
:
;
;
.
8.5.7. ,
,
(
). ,
.
( A, I Gilbody et al,
2006; A, II, Rush et al, 2006).

8.5.8.

8.5.8.1.

( ,

)
:
,

;
, ,
.
8.5.8.2. ,

, 1620
34 .
, :
23 ;
46 6 .
8.5.8.3. 815
, 2 8
, 12
( B, II, Klein et al, 2004).

8.5.9.

8.5.9.1. ,

.
: , ,
, , .
,
( 1 ),
. ,
, , (
( 6)
8.5.9.2. ,

4 .
,
(, ) .
 , ,
.
8.5.9.3. ,

.
:
.
;

( ,
)
.

8.6. 4 : ( 5)

,
,

8.6.1.
8.6.1.1. ,
:
, ,
, ;
,
,
;
,
.
8.6.1.2.
.

.
8.6.1.3. ,

(,
) ,
. (
, 9)
8.6.1.4. ,

8.6.1.5.
(, , ,
, ) (
, )
.
:

;
,

;
.

8.6.2. ,

8.6.2.1. , ,

,
;
8.6.2.2. ( )
,


.
8.6.2.3. ,

8.6.3.

8.6.3.1.

( ).

8.6.4. ()

8.6.4.1.
. .
,
.
, .
8.6.4.2.
. ,

.
8.6.4.3. ,

, .
8.6.4.4. ,

,
.
8.6.4.5. , ,

, :
;
;
/
.
8.6.4.6. ,

.
, :
;
;
, ;
.
.

8.6.4.7. ,

.
. , :

;
,
;


;
,
, ,
/ .
8.6.4.8.

. :
, ,
;
,
,
.
8.6.4.9.
(, ).

.
8.6.4.10.

34 .
8.6.4.11. :

;
24 ,

.
8.6.4.12. ,

, ,
,
, .
8.6.4.13.
.
.

8.6.5.
8.6.5.1.

.
,
,
,
, . ,

.
 9.

, ,
( ,
), .
,

.
,
.

.

9.1. :

9.1.1.

,
;
,

;

.
.

/ ;

( ) ;

,
, ;

;

.

9.1.2.
,
;
,
,
;
,
.
, ;
,
, ,
;

;
:
,
 ( ,
, ).

9.1.3. ( ( )

:
;
(
).

.
(
.
( 8):
;

(
);


;

;
, ,
, .
 9.1.4.

,
, :

;

.
:
;

;
, .

;
,
, 2 . 3
24 .
;
30

.
:
,
;

;
,
2 .
, ;
,
6 .

9.1.5.
4
( );

( ).

9.2.

(3040%).
.
,
.
9.2.1.

. ,
, ,
.
, .
.
.
9.2.2.




* .
**
(, ).
*** .

(
).
, .
, , .
.

. .

9.3.

:

;


;

.
,
,
.

9.3.1.

:
,
;
, ;

;

, .

10.

.
, ,
, .
,
(
, , ). 20%
.
:
;
, ,
,
,
. , ,
;


.

11.

11.1. ( 9)

,
.
:
,
;

;
,
;

;
 20
;

;
,
,
( ( 6);

,
;
,

,
;

3
.

11.2.

: : ,
, , ( )

, ;

;

;
20
;

, ;
,
;

;
, ,
.

;
;

, ,
( 2 );
.

, :


;

;

(spina bifida) ;
;
18 ;

, ;

;
, .

12.

3 .

13.

-
, ,
2011 .
,

. 369- 100
,
(
, ,
 -,
). .

14.

()
(, ,
, )
,

.

( 10).

15.

:
1.
;
2. ,

-.
3.
;
4.
.
 16.

( 1)

ICD-10 DSM-IV
F32 296.2
F32.0 296.21
F32.1 296.22
F32.2 296.23
F32.3 296.24
F32.8

F33 296.3
F33.0
F33.1
F33.2



F33.3


F33.4
F34.1 300.4
F06.32
293.82

F38.10
 ( 2)

*,

:
-

- ,





**

- .



***,

*
**
*** - *
 - ( 3)
- : , ,
, , ,

: ,

: , ,
, , ,
,
: ,
,

: , ,

: , , ,
, ,

 ( 4)
- , , ,
- , ;
- : , , , ,
, (
), ;
- : TA- ,
( ,
);
- : ,
, , , ,
;.

- , , ,
;
- .
:
- 16-32 ;
-;
;
;
- .
 - ( 5)
, , ,
, , ,
, ,
,
, , ,
,
, ,
, ,
,
(),
()

( 6)

, , ,
, , ,
, ,
* - ,
, , ,
, , ),

*
, ,,
, , , ,
, .
* - ,
.

( 7)

,

(,
)
, ,
,

(

)
.
,

,


, ,

MAO-B
(, ) , ,

, ,


(
)
()

 ( 8)

II
.
;

HbA 1c ,
.

;
,
(2 )

,

,
( ).

HbA 1c .










, ,
,

,

 ( 9)

,


.
. :

,



,
:
*

:
*
,












**


*
**
 ( 10)
National Health and
(Muir Gray) Medical Research
(Cook et al) Council
www.nhmrc.gov.au
I , A I



(-),






.
II , B I







III , C III

,

-

.
.
IV D IV
V


Va


Vb ,



 17.

,
-4 : *
, ,
, ,

-3 : ,

, ,
, **

-2 : ,
,

, ,
: ,



 I ( 2)
I ( 2)
:
-
?

?

""

:
:
- ?
- ?
- ?
, :
/


.
,
. ,

, ,
:
( ),
-
,


.
.
 II ( 3)

, :

,

:
() ,


, ,
,

,
, :
-

, ,
, :
()

( 2 )


 III ( 4)

, ,

()
,


 IV ( 5)

, ,

 18.

( 1)

A1 ,
, ?

(
) ?

A2 ( , , )

?

B1 (
, , ) ?

B2 ?

B3
( ,
, ) ?

/
(problem solving)



( )
?

, ?

, (, ,
) ?

B4

?

B5 ?

C1 ( , ,
) ?

(, )
C2 ( , ,
)
?

( )

C3 ,
,
?

C4
( )?

C5
?

C6 , ,
( , ,
) ?

C7 (
, , )
?

C8 ?

C9 (
,
) ( , ,
), ?

D1
? ,
, , , ..

E1
?
E2
?
 ( 2)
N
1
0
(
1
)

2

2
, 0
, 1
, 2
3 ,
/
0
, ,
,
1
(.
)
( ) 2
4 , ,

0
,
1

2
5

0

1
(. )
( ,
2
)
6
0
1
2
7
0

1
, /
2
8
12
0
1
, 2
9
0
, ,
1

2
=
13
Beck et al.1974; Pallis & Pierce 1979
 19. :

1 Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de

Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC,
Kovess V, Lpine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J,
Arbabzadeh-Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M,
Domingo-Salvany A, Ferrer M, Joo SS, Martnez-Alonso M, Matschinger H,
Mazzi F, Morgan Z, Morosini P, Palacn C, Romera B, Taub N, Vollebergh WA;
Prevalence of mental disorders in Europe: results from the European Study of
the Epidemiology of Mental Disorders (ESEMeD) project. ESEMeD/MHEDEA
2000 Investigators, European Study of the Epidemiology of Mental Disorders
(ESEMeD) Project. Acta Psychiatr Scand Suppl. 2004;(420):21-7.
2 Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H, de
Girolamo G, Graaf R, Demyttenaere K, Gasquet I, Haro JM, Katz SJ, Kessler RC,
Kovess V, Lpine JP, Ormel J, Polidori G, Russo LJ, Vilagut G, Almansa J,
Arbabzadeh-Bouchez S, Autonell J, Bernal M, Buist-Bouwman MA, Codony M,
Domingo-Salvany A, Ferrer M, Joo SS, Martnez-Alonso M, Matschinger H,
Mazzi F, Morgan Z, Morosini P, Palacn C, Romera B, Taub N, Vollebergh WA;
Disability and quality of life impact of mental disorders in Europe: results from
the European Study of the Epidemiology of Mental Disorders (ESEMeD)
project. ESEMeD/MHEDEA 2000 Investigators, European Study of the
Epidemiology of Mental Disorders (ESEMeD) Project. Acta Psychiatr Scand
Suppl. 2004;(420):38-46.
3 Anderson M. Waiting for harm: deliberate self-harm and suicide in young
people--a review of the literature. J Psychiatr Ment Health Nurs. 1999
Apr;6(2):91-100.
4 Anderson SI, Taylor R, Whittle IR. Mood disorders in patients after treatment
for primary intracranial tumours. Br J Neurosurg. 1999 Oct;13(5):480-5.
5 Angst J. On the etiology and nosology of endogenous depressive psychoses. A
genetic, sociologic and clinical study. 1966. Monogr Gesamtgeb Neurol
Psychiatr. 1966;112:1-118.
6 Ayen I, Hautzinger M: [Cognitive behavior therapy for depression in
menopausal women: a controlled, randomized treatment study]. Zeitschrift fur
Klinishe Psychologie und Psychotherapie 2004;290 299
7 Baldwin, D. S., Stein, D. J., Dolberg, O. T., et al. (2009) How long should a trial
of escitalopram treatment be in patients with major depressive disorder,
generalized anxiety disorder or social anxiety disorder? An exploration of the
randomized controlled trial database. Human Psychopharmacology: Clinical
and Experimental, 24, 269275.
 8 Barbey, J. T. & Roose, S. P. (1998) SSRI safety in overdose. Journal of Clinical
Psychiatry, 59 (Suppl. 15), 4248.
9 Barkow, K., Heun, R., Wittchen, H. U., et al. (2004) Mixed anxiety-depression
in a 1 year follow-up study: shift to other diagnoses or remission? Journal of
Affective Disorders, 79, 235239.
10 Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J.An inventory for
measuring depression. Arch Gen Psychiatry. 1967 Jun;4:561-71.
11 Beck. AT. (1976) Complex cognitive therapy and the emotional disorder.
International Universities Press. NY
12 Beekman AT, Copeland JR, Prince MJ. Review of community prevalence of
depression in later life. Br J Psychiatry. 1999 Apr;174:307-11.
13 Bertelsen A, Harvald B, Hauge M. A Danish twin study of manic-depressive
disorders. Br J Psychiatry. 1977 Apr;130:330-51
14 Bhugra, D. & Cochrane, R. (2001) Psychiatry in a multi-ethnic context. In
Psychiatry in Multicultural Britain (eds D. Bhugra & R. Cochrane). London:
Gaskell.
15 Bottonari KA, Roberts JE, Kelly MA, Kashdan TB, Ciesla JA. A prospective
investigation of the impact of attachment style on stress generation among
clinically depressed individuals.Behav Res Ther. 2007 Jan;45(1):179-88.
16 Bower, P. & Gilbody, S. (2005a) Stepped care in psychological therapies: access,
effectiveness and efficiency: narrative literature review. British Journal of
Psychiatry, 186, 1117
17 Brown WJ, Ford JH, Burton NW, Marshall AL, Dobson AJ: Prospective study of
physical activity and depressive symptoms in middle-aged women. Am J Prev
Med 2005; 29:265272
18 Buckley, N. A., Dawson, A. H., Whyte, I. M., et al. (1994) Greater toxicity in
overdoseof dothiepin than of other tricyclic antidepressants. Lancet, 343, 159
162.
19 Bucknall, C., Brooks, D., Curry, P. V., et al. (1988) Mianserin and trazodone for
cardiac patients with depression. European Journal of Clinical Pharmacology,
33, 565569.
20 Burke MJ, Preskorn SHTherapeutic drug monitoring of antidepressants: cost
implications and relevance to clinical practice. Clin Pharmacokinet. 1999
Aug;37(2):147-65.
21 Carroll BJ. The dexamethasone suppression test for melancholia. Br J
Psychiatry. 1982 Mar;140:292-304
22 Cassano P, Fava M. Depression and public health: an overview. J Psychosom
Res. 2002 Oct;53(4):849-57.
23 Cipriani A, Pretty H, Hawton K, Geddes JR: Lithium in the prevention of
suicidal behavior and allcause mortality in patients with mood disorders: a
systematic review of randomized trials. Am J Psychiatry 2005; 162:18051819
24 Cochrane Database of Systematic Reviews; Gartlehner et al., 2008; NICE, 2004a
25 Cohen GD. Promoting mental health, treating mental illness. Broadening the
focus on intervention. Geriatrics. 2002 Jan;57(1):47-8.
26 Coyne JC, Thompson R, Pepper CM. The role of life events in depression in
primary medical care versus psychiatric settings. J Affect Disord. 2004 Nov
1;82(3):353-61.
27 D.Taylor, C. Paton, Sh. Kapur. Maudsley Prescribing Guidelines in Psychiatry
11th Edition 2012. Kings College London, IoP.
28 D.Taylor, C. Paton, Sh. Kapur. Maudsley Prescribing Guidelines in Psychiatry.
10th edition, 2009. Kings College London, IoP.
29 Davis JM, Smith R, Dekirmenjian H, Garver D. Antipsychotic plasma levels and
effectiveness (proceedings. Ann Med Psychol (Paris). 1979 Mar-Apr;137(3-
4):214-5.
30 Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition,
American Psychiatric Association ,1994 (DSM-IV).
31 Dolder CR, Nelson M, Snider M Agomelatine treatment of major depressive
disorder. Ann Pharmacother. 2008 Dec;42(12):1822-31.
32 Drevets WC, Price JL, Furey ML. Brain structural and functional abnormalities
in mood disorders: implications for neurocircuitry models of depression. Brain
Struct Funct. 2008 Sep;213(1-2):93-118.
33 Drevets WC, Savitz J, Trimble M. The subgenual anterior cingulate cortex in
mood disorders. CNS Spectr. 2008 Aug;13(8):663-81.
34 Eagles JM. Seasonal affective disorder: a vestigial evolutionary advantage? Med
Hypotheses. 2004;63(5):767-72.
35 European Medicines Agency, 2009
36 Geddes JR, Freemantle N, Mason J, Eccles MP, Boynton J: SSRIs versus other
antidepressants for depressive disorder. Cochrane Database Syst Rev 2000;
37 Gilbody, S., Bower, P., Fletcher, J., et al. (2006) Collaborative care for
depression: a cumulative meta-analysis and review of longer-term outcomes.
Archives of Internal Medicine, 166, 23142321.
38 Gilbody, S., Bower, P., Fletcher, J., et al. (2006) Collaborative care for
depression: a cumulative meta-analysis and review of longer-term outcomes.
Archives of Internal Medicine, 166, 23142321.
39 Goodwin GM, Emsley R, Rembry S, Rouillon F; Agomelatine Study Group.
Agomelatine prevents relapse in patients with major depressive disorder
without evidence of a discontinuation syndrome: a 24-week randomized,
double-blind, placebo-controlled trial. J Clin Psychiatry. 2009 Aug;70(8):1128-
37.
40 Grahame-Smith DG. Serotonin in affective disorders. Int Clin
Psychopharmacol. 1992 Jun;6 Suppl 4:5-13
41 Griez EJ, Faravelli C, Nutt DJ, Zohar J (2005) Mood disorders: clinical
management and research issues. John Wiley, Chichester. (Multi-author
textbook with comprehensive coverage of clinical research and management of
mood disorders.)
42 H.I.Kaplan, B.J.Sadock Comprehensive Textbook of Psychiatry, eight edition,
2007
43 Harris, E. C. & Barraclough, B. (1997) Suicide as an outcome for mental
disorders. A meta-analysis. British Journal of Psychiatry, 170, 205228.
44 International Statistical Classification of Diseases and Related Health Problems
10th Revision , current version, World Health Organization.
45 Jenkins R, Rose J, Lovell C. Psychological well-being of staff working with
people who have challenging behaviour. J Intellect Disabil Res. 1997 Dec;41 (
Pt 6):502-11.
46 Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors.
JAMA. 2004 Jul 21;292(3):338-43.
47 Joyce PR, Doughty CJ, Wells JE, Walsh AE, Admiraal A, Lill M, Olds RJ.
Affective disorders in the first-degree relatives of bipolar probands: results from
the South Island Bipolar Study. Compr Psychiatry. 2004 May-Jun;45(3):168-74.
48 Judd F, Murray G, Fraser C, Humphreys J, Hodgins G, Jackson H. The mental
health of rural Australians: developing a framework for strategic research. Aust
J Rural Health. 2002 Dec;10(6):296-301.
49 Judd LL. A decade of antidepressant development: the SSRIs and beyond. J
Affect Disord. 1998 Dec;51(3):211-3
50 Katon W, Von Korff M, Lin E, Simon G. Rethinking practitioner roles in
chronic illness: the specialist, primary care physician, and the practice
nurse.Gen Hosp Psychiatry. 2001 May-Jun;23(3):138-44
51 Katon WJ, Schoenbaum M, Fan MY, Callahan CM, Williams J Jr, Hunkeler E,
Harpole L, Zhou XH, Langston C, Untzer J. Cost-effectiveness of improving
primary care treatment of late-life depression. Arch Gen Psychiatry. 2005
Dec;62(12):1313-20.
52 Katon WJ, Von Korff M, Lin EH, Simon G, Ludman E, Russo J, Ciechanowski
P, Walker E, Bush T. The Pathways Study: a randomized trial of collaborative
care in patients with diabetes and depression. Arch Gen Psychiatry. 2004
Oct;61(10):1042-9.
53 Kazantzis, N., Deane, F. P. & Ronan, K. R. (2000) Homework assignments in
cognitive and behavioral therapy: a meta-analysis. Clinical Psychology: Science
and Practice, 7, 189202.
54 Keller MB, McCullough JP, Klein DN, Arnow B, Dunner DL, Gelenberg AJ,
Markowitz JC, Nemeroff, CB, Russell JM, Thase ME, Trivedi MH, Zajecka J: A
comparison of nefazodone, the cognitive behavioral-analysis system of
psychotherapy, and their combination for the treatment of chronic depression.
 N Engl J Med 2000; 342:14621470

55 Kennedy SE, Koeppe RA, Young EA, Zubieta JK.. Dysregulation of endogenous
opioid emotion regulation circuitry in major depression in women. Arch Gen
Psychiatry. 2006 Nov;63(11):1199-208.
56 Khan RA, Pathan TZ, Uddin MM. Factors affecting the early discharge of the
indoor psychotic patients - a sociodemographic survey in a specialized
institution. Mymensingh Med J. 2003 Jul;12(2):78-81
57 Khan, N., Bower, P. & Rogers, A. (2007) Guided self-help in primary care
mental health: meta-synthesis of qualitative studies of patient experience.
British Journal of Psychiatry, 191, 206211.
58 Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., et al. (2008) Initial severity and
antidepressant benefits: a meta-analysis of data submitted to the Food and Drug
Administration. Public Library of Science Medicine, 5, 260268.
59 Klein DN, Santiago NJ, Vivian D, Blalock JA, Kocsis JH, Markowitz JC,
McCullough JP Jr, Rush AJ, Trivedi MH, Arnow BA, Dunner DL, Manber R,
Rothbaum B, Thase ME, Keitner GI, Miller IW, Keller MB: Cognitive-
behavioral analysis system of psychotherapy as a maintenance treatment for
chronic depression. J Consult Clin Psychol 2004; 72:681688
60 Kocsis JH, Thase ME, Trivedi MH, Shelton RC, Kornstein SG, Nemeroff CB,
Friedman ES, Gelenberg AJ, Dunner DL, Hirschfeld RM, Rothschild, AJ,
Ferguson JM, Schatzberg AF, Zajecka JM, Pedersen, RD, Yan B, Ahmed S,
Musgnung J, Ninan PT, Keller MB: Prevention of recurrent episodes of
depression with venlafaxine ER in a 1-year maintenance phase from the
PREVENT Study. J Clin Psychiatry 2007; 68:10141023
61 Kraepelin, E (1921) Manic-depressive insanity and paranoia (transl. R.M.
Barclay), Churchill Livingstone, Edinburgh, pp. 1-164. Reprinted in 1976 by
Arno Press, New York. (The classical account. See especially description of
untreated mania seldom seen today) Jamison, KR (1997) An unquiet mind.
Picador, London. (A superb autographical account of the experience of bipolar
illness and its treatment.)
62 Kuehner C, Buerger C. Determinants of subjective quality of life in depressed
patients: the role of self-esteem, response styles, and social support. J Affect
Disord. 2005 Jun;86(2-3):205-13.
63 Kuehner C. An evaluation of the 'Coping with Depression Course' for relapse
prevention with unipolar depressed patients. Psychother Psychosom.
2005;74(4):254-9
64 Lewinsohn PM, Zeiss AM, Duncan EM. Probability of relapse after recovery
from an episode of depression. J Abnorm Psychol. 1989 May;98(2):107-16.
65 Lewis AJ. Health as a Social Concept. 1956. British Journal of Sociology
66 Lewis, AJ (1934) Melancholia: a clinical survey of depressive states. Journal of
Mental Science 80, 277-378, Reprinted in Lewis, AJ (1967) Inquires in
Psychiaty, Routledge and Kegan Paul, London, pp. 30-117. (This landmark
study contains a detailed account of the clinical picture of depressive disorder.)
67 M.Gelder, D.Gath, R.Meyou, Ph.Cowen - Oxford Textbook in Psychiatry,
Reprinted 2009;
68 MacMillan, H. L., Patterson, C. J. & Wathen, C. N. (2005) Screening for
depression in primary care: recommendation statement from the Canadian
Task Force on Preventive Health Care. Canadian Medical Association Journal,
172, 3335.
69 Mann, T. (1996) Clinical Guidelines: Using Clinical Guidelines to Improve
Patient. Care Within the NHS. London: NHS Executive.
70 Mazure CM, Maciejewski PK. The interplay of stress, gender and cognitive
style in depressive onset. Arch Womens Ment Health. 2003 Feb;6(1):5-8.
71 McAskill R, Mir S, Taylor DPindolol augmentation of antidepressant therapy.
Br J Psychiatry. 1998 Sep;173:203-8.
72 Mitchell, A. J., Vaze, A. & Rao, S. (2009) Clinical diagnosis of depression in
primary care: a meta-analysis. Lancet, 374, 609619.
73 Montgomery P, Tompkins C, Forchuk C, French S. Keeping close: mothering
with serious mental illness. J Adv Nurs. 2006 Apr;54(1):20-8.
74 Montgomery S, Serretti A, Zohar J, Mendlewicz J; Group for the Study of
Resistant Depression. Clinical factors associated with treatment resistance in
major depressive disorder: results from a European multicenter study. J Clin
Psychiatry. 2007 Jul;68(7):1062-70.
75 NICE (2004a) Depression: Management of Depression in Primary and
Secondary Care. Clinical Guideline 23. London: NICE.
76 Nicholson, A., Kuper, H. & Hemingway, H. (2006) Depression as an aetiologic
and prognostic factor in coronary heart disease: a meta-analysis of 6362 events
among 146,538 participants in 54 observational studies. European Heart
Journal, 27, 27632774.
77 Nierenberg AA, Fava M, Trivedi MH, Wisniewski, SR, Thase ME, McGrath PJ,
Alpert JE, Warden D, Luther JF, Niederehe G, Lebowitz B, Shores-Wilson K,
Rush AJ: A comparison of lithium and T(3) augmentation following two failed
medication treatments for depression: a STAR*D report. Am J Psychiatry 2006;
163:15191530
78 Ofman, J. J., Badamgarav, E., Henning, J. M., et al. (2004) Does disease
management improve clinical and economic outcomes in patients with chronic
diseases? A systematic review. American Journal of Medicine, 117, 182192.
79 Palmer, S. C. & Coyne, J. C. (2003) Screening for depression in medical care:
pitfalls, alternatives, and revised priorities. Journal of Psychosomatic Research,
 54, 279287

80 Paykel ES, Myers JK, Dienelt MN, Klerman GL, Lindenthal JJ, Pepper MP. Life
events and depression. A controlled study. Arch Gen Psychiatry. 1969
Dec;21(6):753-60.
81 Paykel ES, Rassaby E. Classification of suicide attempters by cluster analysis. Br
J Psychiatry. 1978 Jul;133:45-52.
82 Paykel ES, Weissman MM, Prusoff BA. Social maladjustment and severity of
depression. Compr Psychiatry. 1978 Mar-Apr;19(2):121-8.
83 Paykel ES. Antidepressants in the 1990s. Epidemiol Psichiatr Soc. 2000 Jul-
Sep;9(3):152-5.
84 Paykel ES. Contribution of life events to causation of psychiatric illness.
Psychol Med. 1978 May;8(2):245-53
85 Paykel, E. S., Freeling, P. & Hollyman, J. A. (1988) Are tricyclic antidepressants
useful for mild depression? A placebo-controlled trial. Pharmacopsychiatry, 21,
1518.
86 Pezawas L, Angst J, Gamma A, Ajdacic V, Eich D, Rssler W. Recurrent brief
depression--past and future. Prog Neuropsychopharmacol Biol Psychiatry. 2003
Feb;27(1):75-83. Review.
87 Pezawas L, Wittchen HU, Pfister H, Angst J, Lieb R, Kasper S. Recurrent brief
depressive disorder reinvestigated: a community sample of adolescents and
young adults. Psychol Med. 2003 Apr;33(3):407-18.
88 Practice Guideline for The treatment and management of depression in adults.
(2009) National Institute for Health and Clinical Excellence NICE,
89 Practice Guideline for the Treatment of Patients With Major Depressive
Disorder, Third Edition, (2010), American Psychiatric Association.
90 Prasher, V. (1999) Presentation and management of depression in people with
learning disability. Advances in Psychiatric Treatment, 5, 447454.
91 Price TR, Tucker GJ. Psychiatric and behavioral manifestations of normal
pressure hydrocephalus. A case report and brief review. J Nerv Ment Dis. 1977
Jan;164(1):51-5.
92 Quitkin FM, Stewart JW, McGrath PJ, Tricamo E, Rabkin JG, Ocepek-
Welikson K, Nunes E, Harrison W, Klein DF (1993): Columbia atypical
depression: A subgroup of depressives with better responses to MAOI than to
tricyclic antidepressants or placebo. Br J Psychiatry 163(Suppl 21):30-34
93 Ridge, D. & Ziebland, S. (2006) The old me could never have done that: how
people give meaning to recovery following depression. Qualitative Health
Research, 16, 10381053.
94 Roberts, D., Bernard, M., Misca, G., et al. (2008) Experiences of Children and
Young People Caring for a Parent with a Mental Health Problem. Research
Briefing No. 24. London: Social Care Institute for Excellence.
 95 Roose, S. P. (2003) Treatment of depression in patients with heart disease.
Biological Psychiatry, 54, 262268.
96 Rosenthal LJ, Goldner WS, O'Reardon JP. T3 augmentation in major depressive
disorder: safety considerations. Am J Psychiatry. 2011 Oct;168(10):1035-40
97 Roth, A. J., Kornblith, A. B., Batel-Copel, L., et al. (1998) Rapid screening for
psychologic distress in men with prostate carcinoma: a pilot study. Cancer, 82,
19041908.
98 Rush, A. J., Trivedi, M. H., Wisniewski, S. R., et al. (2006) Acute and longer-
term outcomes in depressed outpatients requiring one or several treatment
steps: a STAR*D report. American Journal of Psychiatry, 163, 19051917.
99 Smith DJ, Harrison N, Muir W, Blackwood DH. The high prevalence of bipolar
spectrum disorders in young adults with recurrent depression: toward an
innovative diagnostic framework. J Affect Disord. 2005 Feb;84(2-3):167-78.
100 Smith DJ, Muir WJ, Blackwood DH. Neurocognitive impairment in euthymic
young adults with bipolar spectrum disorder and recurrent major depressive
disorder. Bipolar Disord. 2006 Feb;8(1):40-6.
101 Stein DJ, Ahokas AA, de Bodinat C. Efficacy of agomelatine in generalized
anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin
Psychopharmacol. 2008 Oct;28(5):561-6.
102 Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of
depression. Neuropsychopharmacology. 1995 May;12(3):185-219.
103 Wagner P, Rschke J, Fell J, Frank C. Differential pathophysiological
mechanisms of reduced P300 amplitude in schizophrenia and depression: a
single trial analysis. Schizophr Res. 1997 Jun 20;25(3):221-9.
104 Whooley, M. A., Avins, A. L., Miranda, J., et al. (1997) Case-finding
instruments for depression. Two questions are as good as many. Journal of
General Internal Medicine, 12, 439445.
105 Yager J. (1992) Mood disorders and marital and family problems. American
Psychiatric Press Review of Psychiatry, 477493.
 20. :

- , ,
, NHS Trust
, ()

, ,
;
.

, . . /

, , . . /
, .

- , ,

- , ,

, , .

, ,

 , . .

- ,